Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

A Series in The Lancet Neurology provides state-of-the-art reviews covering clinical and scientific evidence on the four most common genetic subtypes of amyotrophic lateral sclerosis (ALS), caused by ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson’s disease, according to results from a phase 1 clinical ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (A?) monoclonal antibody Leqembi® ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...